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The FAS receptor–ligand system plays a key role in regulating apoptotic cell death, and 
corruption of this signaling pathway has been shown to participate in tumor-immune escape 
and carcinogenesis. We have recently demonstrated (Sun, T., X. Miao, X. Zhang, W. Tan, 
P. Xiong, and D. Lin. 2004. 
 
J. Natl. Cancer Inst.
 
 96:1030–1036; Zhang, X., X. Miao, T. Sun, 
W. Tan, S. Qu, P. Xiong, Y. Zhou, and D. Lin. 2005. 
 
J. Med. Genet.
 
 42:479–484) that 
functional polymorphisms in FAS and FAS ligand (FASL) are associated with susceptibility 
to lung cancer and esophageal cancer; however, the mechanisms underlying this association 
have not been elucidated. We show that the FAS –1377G, FAS –670A, and FASL –844T 
variants are expressed more highly on ex vivo–stimulated T cells than the FAS –1377A, FAS 
–670G, and FASL –844C variants. Moreover, activation-induced cell death (AICD) of T cells 
carrying the FASL –844C allele was increased. We also found a threefold increased risk of 
cervical cancer among subjects with the FASL –844CC genotype compared with those with the 
–844TT genotype in a case-control study in Chinese women. Together, these observations 
suggest that genetic polymorphisms in the FAS–FASL pathway confer host susceptibility to 
cervical cancers, which might be caused by immune escape of tumor cells because of 
enhanced AICD of tumor-specific T cells.
 
Activation-induced cell death (AICD) refers
to the induction of apoptosis of previously
activated T cells on subsequent encounter
with antigen (1). This mechanism plays a crucial
role in both central and peripheral deletion
events involved in tolerance and homeostasis
of the immune system (2, 3). Accumulating
evidence also demonstrates that AICD is one
of the important mechanisms responsible for
the increased apoptosis rate among tumor infil-
tration lymphocytes (TILs), which may protect
transformed cells from elimination by antitumor
immune responses and, therefore, contribute
to carcinogenesis and cancer progression (4, 5).
AICD is a FAS ligand (FASL)–dependent
process (6). AICD in peripheral T cells is often
caused by the induction of expression of the
death ligand, FASL. Cytotoxic T cells increase
expression of both FAS and FASL on activation
by antigen or other stimulation and subse-
quently undergo “suicide” or “fratricide” by
FASL liganding to FAS (7, 8). Antigenic stimula-
tion within the tumor microenvironment might
also be involved in the enhanced expression and
function of FASL on T cells, resulting in acti-
vation of autocrine or paracrine mechanisms of
apoptosis (9). FASL-mediated AICD is directly
regulated by the level of this death ligand (1),
whereas FASL transcriptional regulation happens
in both T cells and nonlymphoid cells, such as
a variety of tumor cells. In a tumor microenvi-
ronment, tumor cells can also counterattack by
expressing FASL and inducing the apoptosis of
T cells (10, 11).
Cervical cancer is strongly associated with
infection by oncogenic types of human papil-
loma virus (HPV) (12). However, only a por-
tion of infected individuals develop cervical
cancer during their life, indicating that genetic
factors may also contribute to the formation of
this cancer. A large body of epidemiological
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evidence shows that genetic predisposition to cervical can-
cer may exist (13, 14). It has been shown that cervical tu-
mor cells have the ability to induce apoptosis of activated
tumor cell–specific cytotoxic T lymphocytes, and this
process can be blocked by an inhibitory anti-FAS anti-
body, suggesting that it is mediated by FAS–FASL interac-
tion (15). Because human cervical tumors (HeLas) indeed
express FASL (15–17), these tumor cells are expected to
induce AICD of TILs in vivo. Thus, the expression levels
of FASL and FAS might be of importance in determining
individual susceptibility to cervical cancer development.
Single nucleotide polymorphisms (SNPs) in the promoter
regions of FASL and FAS have been linked to the differential
expression of these two genes. It has been shown that the
T
 
→
 
C transition at position 
 
 
 
844 in the promoter region of
FASL is located in a binding motif for transcription factor
CAAT/enhancer-binding protein 
 
 
 
, and a considerably
higher basal expression of FASL is associated with the FASL
–844C allele compared with the –844T allele (18). In regards
to the FAS gene, G
 
→
 
A transition at position –1377 and
A
 
→
 
G transition at position 
 
 
 
670 in the promoter region de-
stroy stimulatory protein 1 and signal transducer and activator
of transcription 1 protein binding element, respectively, and
thus diminish promoter activity and decrease FAS expression
(19, 20). We have recently shown that these functional poly-
morphisms in FASL and FAS have great impact on suscepti-
bility to cancers of the esophagus and lung (21, 22). The ef-
fect of the FAS polymorphism on the risk of cervical cancer
has been reported, but the studies were limited to the
 
 
 
670A
 
→
 
G polymorphism, and the results were controver-
sial (23–25). To date, no study has been reported to examine
the association between functional polymorphisms in FASL
and the risk for the development of cervical cancer.
We wanted to determine whether the polymorphisms in
FAS–FASL have effects on the expression of FAS and FASL
and AICD of T cells induced by PHA and HeLa cells in
vitro. We also performed a case-control study to examine
the association between FAS–FASL polymorphism and the
risk of cervical cancer.
 
RESULTS
FAS and FASL genotypes and cervical cancer risk
 
Baseline clinical characteristics of cases and controls are summa-
rized in Table I. The age distribution and smoking status in pa-
tients were not significantly different from those in controls
(P 
 
 
 
 0.583 and 0.537, respectively). An absolute majority of
cases (97.8%) was infected with HPV. Of 314 patients, 95.2%
were classified as squamous cell carcinoma, whereas 3.5 and
1.3% were adenocarcinoma and adenosquamous carcinoma, re-
spectively. According to the International Federation of Gyne-
cology and Obstetrics classification, 21.3% of patients had carci-
noma in situ (stage 0), whereas 21.3, 37.6, and 18.5% of patients
had stage I, II, and III disease, respectively. Only 1.3% of pa-
tients had stage IV cervical cancer.
Genotype analyses of FAS and FASL polymorphisms
were successful for all patients, but 13 controls failed to be
 
Table I.
 
Baseline clinical characteristics of cases and controls
 
Patients (
 
n
 
 
 
 
 
 314) Controls (
 
n
 
 
 
 
 
 628) P
 
a
 
No. (%) No. (%)
 
Age (yr) 0.583
 
 
 
40 129 (41.1) 244 (38.8)
41–50 114 (36.3) 223 (35.6)
 
 
 
50 71 (22.6) 161 (25.6)
Smoking status 0.537
Nonsmoker 293 (93.3) 579 (92.2)
Smoker 21 (6.7) 49 (7.8)
HPV infection status
HPV
 
 
 
307 (97.8)
HPV
 
 
 
7 (2.2)
Histological type
Squamous cell carcinoma 299 (95.2)
Adenocarcinoma 11 (3.5)
Adenosquamous carcinoma 4 (1.3)
Clinical stage
 
b
 
Stage 0 67 (21.3)
Stage I 67 (21.3)
Stage II 118 (37.6)
Stage III 58 (18.5)
Stage IV 4 (1.3)
 
a
 
Two-sided 
 
 
 
2
 
 test.
 
b
 
According to the International Federation of Gynecology and Obstetrics classification. 
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genotyped because of PCR amplification problems with
their DNAs (Table II). The allelic frequencies for the FAS
–1377A and FAS –670G alleles were 0.317 and 0.343 in
controls, respectively, compared with 0.312 and 0.332 in pa-
tients. For FASL, the frequencies of the –844C alleles in
controls and patients were 0.699 and 0.792, respectively.
The observed genotype frequencies for both FAS and FASL
in controls and patients conformed to the Hardy-Weinberg
equilibrium. The two FAS polymorphisms are in almost
complete linkage disequilibrium in our study population
(D
 
 
 
 
 
 
 
 0.98; P 
 
 
 
 0.001). Although the distributions of the
FAS –1377G
 
→
 
A and FAS –670A
 
→
 
G genotypes were not sig-
nificantly different between cases and controls (P 
 
 
 
 0.909 and
0.652, respectively), the frequencies for the FASL –844T
 
→
 
C
genotypes among cases were significantly different from
those among controls (
 
 
 
2
 
 
 
 
 
 20.59; P 
 
 
 
 0.0001), and this dif-
ference was mainly caused by a higher frequency of the CC
genotype among cases compared with controls (61.5 vs.
46.2%). However, no difference in the distribution of FAS
and FASL genotypes among different histological types and
different clinical stages of the cancer were observed (unpub-
lished data). Multivariate regression analyses revealed that
subjects carrying the FASL –844CC genotype had a three-
fold increased risk of developing cervical cancer (odds ratio
[OR] 
 
 
 
 3.05; 95% confidence interval [CI] 
 
 
 
 1.43–6.52;
P 
 
 
 
 0.004) compared with those carrying the TT genotype.
The heterozygous CT genotype also presented a higher risk
for the cancer (OR 
 
 
 
 1.68; 95% CI 
 
 
 
 0.78–3.66), although
the association was not statistically significant (P 
 
 
 
 0.187).
In the stratification analysis, age and smoking had no effect
on the risk of cervical cancer related to FASL genotypes (un-
published data). Because of tight linkage, the haplotype of
FAS 
 
 
 
1377G
 
→
 
A and FAS 
 
 
 
670A
 
→
 
G did not further in-
crease the risk of the cancer (unpublished data). In view of
the fact that FAS and FASL work together in apoptotic cell
death, we examined whether there was a statistical interac-
tion between the SNP in FAS and FASL that was associated
with the risk of cervical cancer. However, no such interac-
tion was evident (unpublished data).
 
FAS and FASL genotypes and their expression on T cells
 
To determine the effects of the SNPs in FAS and FASL on
expression of the genes, PBMCs isolated from 40 healthy
donors carrying different genotypes were incubated with
PHA or mitomycin C (MMC)–treated HeLa cells. The pro-
portion of CD25
 
 
 
/CD4
 
 
 
 cells to CD3
 
 
 
 cells was deter-
mined as an index of T cell activation. In addition, the levels
of IL-2 in the supernatants of culture media of PBMCs were
also determined as an indicator of T cell activation. It was
found that the proportion of CD25
 
 
 
/CD4
 
 
 
 cells (mean 
 
 
 
SD, 
 
n
 
 
 
 
 
 40) in the PBMC cultures with PHA was 50.83 
 
 
 
14.08%, which was significantly higher than that in the cul-
tures without PHA (2.27 
 
 
 
 0.88%; P 
 
 
 
 0.001). In parallel,
the IL-2 level (mean 
 
 
 
 SD, 
 
n
 
 
 
 
 
 40) in the PBMC culture
media with PHA was significantly higher than that in the
PBMC culture media without PHA (191.25 
 
 
 
 66. 41 pg/ml
vs. 28.82 
 
 
 
 15.39 pg/ml; P 
 
 
 
 0.001). Similarly, the propor-
tion of CD25
 
 
 
/CD4
 
 
 
 cells was significantly elevated when
PBMCs were incubated with MMC-treated HeLa cells
compared with those incubated without MMC-treated
HeLa cells (9.98 
 
 
 
 3.32% vs. 6.83 
 
 
 
 2.61%; P 
 
 
 
 0.001).
The activation of T cells by HeLa antigen was also evi-
denced by the fact that the mean IL-2 level in the PBMC
culture media incubated with HeLa cells was significantly
higher than that in the PBMC culture media without HeLa
cells (150.63 
 
 
 
 48.05 pg/ml vs. 98.93 
 
 
 
 53.47 pg/ml; P 
 
 
 
0.001). These results demonstrated that both PHA and HeLa
cell antigens were able to activate PBMCs under our study
 
Table II.
 
Allele and genotype frequencies of FAS and FASL among controls and cases and their association with cervical cancer
 
Genotype Controls (
 
n
 
 
 
 
 
 615) Patients (
 
n
 
 
 
 
 
 314) OR
 
a
 
 (95% CI) P
 
No. (%) No. (%)
 
FAS –1377G
 
→
 
A
GG 282 (45.8) 144 (45.9) reference
AG 277 (45.1) 144 (45.9) 1.01 (0.75–1.37) 0.934
AA 56 (9.1) 26 (8.2) 0.87 (0.51–1.49) 0.617
A allele frequency 0.317 0.312
FAS –670A
 
→
 
G
AA 268 (43.6) 138 (43.9) reference
AG 272 (44.2) 144 (45.9) 1.09 (0.81–1.47) 0.850
GG   75 (12.2) 32 (10.2) 0.85 (0.53–1.36) 0.425
G allele frequency 0.343 0.332
FASL –844T
 
→
 
C
TT 40 (6.5) 10 (3.2) reference
CT 291 (47.3) 111 (35.3) 1.68 (0.78–3.66) 0.187
CC 284 (46.2) 193 (61.5) 3.05 (1.43–6.52) 0.004
C allele frequency 0.699 0.792
 
a
 
Data were calculated by unconditional logistic regression, adjusting for age and smoking status. 
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conditions. Moreover, neither the elevated population of
CD25
 
 
 
/CD4
 
 
 
 cells nor IL-2 concentration in the media
was correlated to FAS –1377, FAS –670, or FASL –844 ge-
notypes (unpublished data).
Next, we examined whether the FAS –1377 or FAS
–670 and FASL –844 SNPs had effects on the expression of
FAS and FASL on T cells in PHA- or HeLa cell–stimulated
PBMCs. The representative flow cytometry determination
of FAS and FASL expression is shown in Fig. 1, A and B.
We observed a significant difference (P 
 
 
 
 0.05) in the FAS
expression on T cells after incubation with PHA as a func-
tion of FAS genotype (Fig. 1 C). The FAS –1377GG or GA
genotype had a significantly heightened FAS expression lev-
els (mean 
 
  
 
SD) compared with the AA genotype (66.63 
 
 
 
3.53% [
 
n
 
 
 
 
 
 12] and 57.92 
 
 
 
 2.61% [n   22] vs. 46.31  
5.02% [n   6]; P   0.002 and 0.048, respectively), whereas
the levels were not significantly different (P   0.355) be-
tween the GG and GA genotype. Similar results were ob-
tained for the FAS –670 polymorphism, which is in almost
complete linkage disequilibrium with the FAS –1377 poly-
morphism. However, the expression of FAS in PBMCs in-
cubated with HeLa cells among three genotypes was not sta-
tistically significant (P   0.05; Fig. 1 C). For FASL
expression after stimulation by PHA, the FASL –844CC ge-
notype had significantly higher levels than the CT or TT ge-
notype (1.72   0.10% [n   18] vs. 1.22   0.10% [n   18]
and 0.32   0.25% [n   4]; P   0.002 and P   0.0001, re-
spectively), and the difference between the heterozygous CT
genotype and the variant homozygous TT genotype was also
statistically significant (P   0.002). After stimulation by
HeLa cells, the FASL expression in subjects with the CC ge-
notype was 0.48   0.04%, which was significantly higher
than that in subjects with the CT (0.36   0.03%; P  
0.018) or TT (0.19   0.09%; P   0.004) genotypes, al-
though the levels between the CT and TT genotypes were
not statistically different, possibly because of limited statistical
power (Fig. 1 D). These findings clearly demonstrated that
the investigated polymorphisms in the promoter region of
FAS and FASL have a substantial impact on the activation-
induced expression of FAS and FASL on T cells.
FAS and FASL genotypes and AICD of T cells
To examine the effects of FAS and FASL genotypes on AICD
of T cells, PBMCs incubated with PHA or HeLa cells were
labeled with FITC–Annexin V, propidium iodide (PI), and
PerCP-Cy5.5-CD3, and the proportion of Annexin V  cells
in the CD3  gate were determined by flow cytometry (Fig. 2
A). We found that neither FAS nor FASL genotypes had an
effect on the spontaneous apoptosis of T cells during culture.
However, when T cells were incubated with either PHA or
HeLa cells, the differences in AICD among three different
FASL –844 genotypes were striking. As shown in Fig. 2 B, af-
ter incubation with HeLa cells, the mean proportion ( SD)
of Annexin V  cells was significantly higher in T cells carry-
ing the FASL –844CC genotype (11.59   5.39) compared
with that in T cells carrying the –844CT (7.36   3.45; P  
0.006) or –844TT (6.76   0.34; P   0.068) genotype. Simi-
larly, after incubation with PHA, the differences in AICD of
T cells among three FASL genotypes were also significant,
with the proportion of Annexin V  cells being higher in T
Figure 1. Differential expression of FAS and FASL on CD3  cells 
in PHA- or HeLa cell–stimulated PBMCs from individuals carrying 
different FAS or FASL genotypes. (A and B) Representative flow 
cytometry pictures showing differential FAS or FASL expression in 
different genotypes. Values indicate the percentage of FAS/CD3  and 
FASL/CD3  cells, respectively. (C and D) FAS or FASL expression levels 
on T cells as a function of genotypes. PBMCs from individuals were 
cultured with or without HeLa cell antigen and MMC-treated HeLa cells 
for 72 h or cultured with or without PHA for 6 h. FAS and FASL expression 
levels were adjusted for CD25 and IL-2 levels. FAS expression levels 
(C) on T cells with PHA but not HeLa cells were significantly different 
among three FAS –1377 genotypes (P   0.05). FASL expression levels 
on T cells with both PHA and HeLa cells were significantly different 
among three FASL –844 genotypes (P   0.05).JEM VOL. 202, October 3, 2005 971
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cells carrying the –844CC genotype than that in T cells carry-
ing the –844TC or –844TT genotype (P   0.05 for both).
However, the differences in AICD of T cells stimulated either
with HeLa cells or with PHA were not significant (P   0.05)
among different FAS –1377 genotypes (Fig. 2 C).
DISCUSSION
Nearly every cell in the body has the potential to threaten
the life of an individual if it transforms into cancer. There-
fore, the immune surveillance of T cells plays an essential
role in maintaining homeostasis (1–3). The FAS–FASL sys-
tem regulates the AICD process of T cells, and genetic varia-
tions in these cell death pathway genes may thus influence
susceptibility to cancers. Functional germline and somatic
mutations in the FAS gene, and perhaps also in the FASL
gene, that impair apoptotic signal transduction are associated
with susceptibility to cancer (26–30). We have recently re-
ported that functional SNPs in FAS and FASL increase the
risk of esophageal cancer and lung cancer in a Chinese popu-
lation (21, 22). Cervical cancer is a unique tumor that tightly
links to infection of oncogenic types of HPV. So far, no spe-
cific oncogenes or tumor suppressor genes have been defined
in this cancer (12). Therefore, we performed a case-control
study to investigate whether genetic polymorphisms in FAS
and FASL confer susceptibility to cervical cancer, a typical
viral infection–associated cancer, in a Chinese population.
Based on the analysis of 314 patients and 615 frequency-
matched controls, we found that subjects carrying the FASL
–844CC genotype had a threefold increased risk for cervical
cancer compared with those carrying the FASL –844TT ge-
notype, whereas the FAS polymorphisms seemed not to be
associated with the risk of this cancer. In addition, we ob-
served no associations between genotypes and histological
types or clinical stages of cervical cancer. However, this
might be the result of a limited sample size in each stratum,
and more studies with stronger statistical power would be
helpful to clarify the associations.
FASL –844T→C polymorphism has been shown to have
a substantial impact on promoter activity of the FASL genes
in an in vitro assay system because it is located in a binding
motif for transcription factor CAAT/enhancer-binding pro-
tein   (18). However, little or nothing is known so far about
genotype and phenotype association; i.e., the effect of this
polymorphism on the expression of FASL in vivo in cells.
Our data in the present study provide evidence for the first
time that the –844T→C polymorphism in FASL strongly in-
Figure 2. AICD of T cells in PBMCs from healthy individuals 
carrying different FAS or FASL genotypes determined by flow 
cytometry. (A, top) Annexin V assay was performed to detect the apop-
tosis index by flow cytometry in CD3  cells within a lymphocyte gate. 
Apoptosis index was defined as the ratio of Annexin V /CD3  cells. 
(A, bottom) Representative flow cytometry showing apoptotic cells in 
PBMCs from two individuals with different FASL genotypes after simulation 
by PHA. The percentages of Annexin V  cells are shown. (B and C) The 
relationship between genotypes of FAS and FASL rates of AICD of T cells. 
The FASL –844 genotype but not the FAS –1377 genotype was associated 
with AICD. The FASL –844CC genotype had a significantly higher rate 
(P   0.05) of AICD compared with the FASL –844CT or TT genotype when 
T cells were incubated with HeLa cells or PHA.FASL POLYMORPHISM AND AICD AND CERVICAL CANCER | Sun et al. 972
fluences the expression of FASL ex vivo on T cells stimu-
lated by either cervical cancer cells or PHA. More impor-
tantly, our study demonstrates that the FASL –844C allele,
which had higher expression of FASL on T cells, was associ-
ated with an enhanced rate of AICD of T cells. This geno-
type and phenotype correlation between FASL –844T→C
polymorphism and AICD of T cells was consistent with mo-
lecular epidemiological findings, demonstrating the FASL
–844C allele as an at-risk allele for cervical cancer. Because
FASL–FAS–mediated AICD is considered to be one of the
important mechanisms responsible for the TIL apoptosis oc-
curring in the tumor microenvironment (4–7), individuals
carrying the FASL –844C allele and, thus, with higher FASL
expression on T cells on tumor antigenic stimulation would
be anticipated to be susceptible to cancer development. On
the other hand, it has been shown that various types of tu-
mors express FASL, and aberrant FASL expression has been
linked to cervical carcinogenesis and tumor progression (15–
17). Because of the functional consequence of the FASL
–844T→C polymorphism, it would be expected that indi-
viduals carrying the FASL –844C allele may also have higher
FASL expression on tumor cells compared with those carry-
ing the FASL –844T allele. Heightened expression of FASL
may facilitate transformed cells to counterattack the FAS-
expressing TILs (4, 10, 11, 15, 31), resulting in immune eva-
sion of these malignant cells. This mechanism may also con-
tribute to an increased risk for developing cervical cancer
among subjects carrying the risk FASL allele.
We did not observe any substantial association between
the investigated functional polymorphisms in FAS and the
rate of AICD of T cells stimulated by PHA or HeLa cells, al-
though the polymorphisms did somewhat influence the ex-
pression of the FAS gene ex vivo on T cells. This finding was
consistent with the population data in the present study but
was inconsistent with our previous results from large molecu-
lar epidemiological studies on esophageal and lung cancer
showing a positive association between the FAS polymor-
phisms and risk of these cancers (21, 22). This discrepancy
may reflect the essential difference in carcinogenesis between
cervical cancer and lung or esophageal cancer. However,
these results may also suggest that, unlike FASL, a subtle
change of widely expressed FAS might not be sensitive
enough to detect a small change of AICD of T cells and the
risk of the cancer. More studies with a larger sample size and
stronger statistical power are needed to get conclusive results.
The data from the genotype–phenotype analysis in the
present study are reliable because our experimental model us-
ing ex vivo PBMCs treated with HeLa cells mimicked the sit-
uation in vivo. HeLa cells are integrated with HPV-18 (32),
and the antigen extracted from these cancer cells contains
HPV oncoproteins, which are suitable for testing the response
of cytotoxic T lymphocytes to both HPV infection and cervi-
cal tumor cells. In addition, it has been shown that HeLa cells
persistently express FASL (15), which allows tumor cells in
our experimental model to counterattack the Fas-expressing
T lymphocytes using the T cell’s own principal mechanism of
cytotoxicity. Finally, all PBMC samples we selected for test-
ing were of the HLA-A2 genotype, which are matched to
HeLa cells (33). Therefore, the T cells sensitized by HeLa cell
antigen could be activated by the following treatment with
HeLa cells. Our results showing increased AICD caused by
interaction of T cells with HeLa cells or PHA clearly demon-
strate that our experimental system is valid.
Although little is known about polymorphisms in FASL
and susceptibility to cervical cancer, at least three studies
have been published regarding the FAS –670 polymorphism
and the risk of cervical cancer. Lai et al. (23) conducted a
study in a Chinese population in Taiwan and reported that
the FAS –670A allele was associated with an increased risk of
squamous intraepithelial lesions and squamous cell carci-
noma. However, Dybikowska et al. (24) and Engelmark et
al. (25) have recently shown that the FAS –670 genotype is
not associated with a risk of the cancer in Caucasian popula-
tions. In this study, we analyzed both FAS –670 and –1377
polymorphisms and found that these two tightly linked poly-
morphisms were not associated with an increased risk of cer-
vical cancer. The reasons for the inconsistent results among
these studies are not clear, but geographic or ethnic differ-
ences in genotype frequencies should be considered, as have
been extensively discussed in our previous reports (21, 34).
In this study with 615 healthy controls, we observed a fre-
quency of 12.2% for the variant FAS –670GG genotype,
which is not significantly different from that reported by Dy-
bikowska et al. (18.5%; P   0.06) but significantly lower
than that reported by Lai et al. (20.5%; P   0.001). The
genotype frequencies are not available in the report of En-
gelmark et al. because of the sib-pair design in their study
(25). These geographic or ethnic differences in genotype fre-
quencies might partially explain the dissimilar results.
Both FAS  670A→G and FAS  1377G→A SNPs
were shown to have a biological impact on the transcrip-
tional activity of the FAS gene, although the effect of
 670A→G is still ambiguous (20, 35). We found a
heightened expression of FAS on T cells stimulated by
PHA that was associated with either the FAS  1377AA or
FAS  670GG genotype. However, the role which SNP
actually plays in influencing the gene expression remains
unclear, because these two SNPs are in almost completely
linkage disequilibrium in our donor population. It would
be interesting and important to distinguish between an ef-
fect at  1377 and the effect at  670, and studies are un-
derway to explore this issue. Another limitation of our
study is that the HPV status of controls is unknown, and
this did not allow us to explore whether the findings re-
flect the association of the genotypes with control of HPV
infection (i.e., the ability to prevent persistent HPV infec-
tion) or the ability to eliminate infected cells before they
undergo the transformation process.
In conclusion, our study demonstrates an association be-
tween the genotype and phenotype of FASL polymorphismJEM VOL. 202, October 3, 2005 973
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and suggests that heightened AICD of T lymphocytes and/
or counterattack of tumor cells against TILs resulting from
functional polymorphisms in the FAS–FASL pathway may
be involved in the mechanism underlying an individual’s
susceptibility to the development of cervical cancer.
MATERIALS AND METHODS
Study subjects. The case-control study consisted of 314 patients with cervi-
cal cancer and 628 controls. All subjects were ethnic Han Chinese and resi-
dents of Beijing and its surrounding regions. Patients were recruited between
June 2001 and March 2002 at the Cancer Hospital, Chinese Academy of Med-
ical Sciences (Beijing, China). All eligible patients diagnosed with cervical car-
cinoma at the hospital during the study period were recruited, with a response
rate of 94%. Healthy controls were from a nutritional survey conducted in the
same region during the period of case collection. The control subjects were
randomly selected from a database consisting of 2,500 individuals based on a
physical examination, including chest radiography and abdominal ultrasonog-
raphy. Gynecological and cervical cytological examinations were also per-
formed. The selection criteria included a history of no cancer or previous op-
erations on the uterine cervix and free of cervical intraepithelial neoplasia.
Controls were frequency matched to cervical cancer patients by age ( 5 yr).
Most control subjects (n   520) were characterized in a breast case control
study as reported previously (36). We added 108 more controls selected from
the same database to make a 2:1 matching to the cases and to increase the sta-
tistical power. For FAS/FASL expression and AICD assays, blood samples
were obtained from a group of 40 healthy volunteers (22 males and 18 females)
working in our institution aged 19–49 yr (mean   SD   31.8   8.6). All
these volunteers were HLA-A2 positive with no history of malignant disease
and clinically evident HPV infection. At recruitment, informed consent was
obtained from each subject, and this study was approved by the Institutional
Review Board of the Chinese Academy of Medical Sciences Cancer Institute.
Genotype analysis. Genotypes of FAS –1377G→A, FAS –670A→G, and
FASL  844T→C polymorphisms were determined by PCR-based restric-
tion fragment length polymorphism assays as described previously (21). All
subjects were successfully genotyped except for 13 controls whose DNA
samples failed to be amplified. To ensure quality control, genotyping was
performed without knowledge of case/control status of the subjects, and a
15% random sample of cases and controls was genotyped twice by different
persons; the reproducibility was 100%.
Antibodies and reagents. PE-labeled mouse anti–human FASL (NOK-1,
IgG1), FITC-labeled mouse anti–human FAS (DX2, IgG1), FITC-labeled
mouse anti–human CD25 (2A3, IgG1), PerCP-Cy5.5–labeled anti–human
CD4 (RPA-T4, IgG1), and PerCP-Cy5.5–labeled mouse anti–human CD3
(OKT3, IgG1) were purchased from BD Biosciences. The Annexin V–FITC
apoptosis detection kit was purchased from BD Biosciences. MMC and
PHA were obtained from Sigma-Aldrich.
HeLa cell culture, antigen preparation, and MMC treatment. HeLa
cells (HLA-A2.1) were cultured in RPMI 1640 medium with 10% FCS, 2
mM glutamine, 100 U/ml penicillin, and 100  g/ml streptomycin at 37 C in
a humidified 5% CO2 atmosphere. For production of HeLa cell antigen, por-
tions of logarithmic growth HeLa cells were collected and washed with cold
PBS. These cells were then shattered by freezing in liquid nitrogen and melted
in a 37 C water bath alternately five times, followed by centrifugation at 2,200 g
for 15 min at 4 C. The supernatants were collected and the total amount of
protein was determined. Another portion of 106 HeLa cells/ml in RPMI 1640
medium was treated with 100 mg/ml MMC for 1 h at 37 C with occasional
shaking to inhibit proliferation. These cells were then washed four times with
the medium before use in the activation of PBMCs as described below.
PBMC isolation and culture. 5   106 PBMC/ml were isolated by Fi-
coll-Paque (Sigma-Aldrich) density-gradient centrifugation and suspended
in RPMI 1640 medium, as used for HeLa cells. PBMCs were distributed
into 24-well tissue culture plates at 1 ml/well and cultured in the presence
of 25  g/ml PHA for 6 h or cultured with 50  g/ml HeLa cell antigen for
the first 4 h, followed by the addition of MMC-treated HeLa cells (1:10
PBMCs) and cultured for the next 68 h. PBMCs cultured without PHA or
HeLa antigen/cells served as respective controls. Cultured PBMCs were
used to assay expression of FAS, FASL, and CD25 and the apoptotic index
among CD3  or CD4  cells, and the cell culture supernatants were col-
lected to determine IL-2 production as described below.
Flow cytometry analysis. A flow cytometer (FACSCalibur; BD Bio-
sciences) was used to determine the cell surface expression of FAS, FASL,
CD25, CD3, and CD4 and cell apoptosis index indicated by Annexin V and
PI staining. Cultured PBMCs, as described above, were washed twice in
cold PBS and incubated in PBS plus 3% FCS with 5  l PE-labeled anti-
FASL, 5  l FITC-labeled anti-FAS, and 5  l PerCP-Cy5.5–labeled anti-
CD3 (tube 1); 5  l FITC-labeled anti-CD25, 5  l PE-labeled anti-CD3,
and 5  l PerCP-Cy5.5–labeled mouse anti-CD4 (RPA-T4, IgG1; tube 2);
or 5  l FITC-labeled Annexin V, 5  l PI staining solution, and 5  l PerCP-
Cy5.5–labeled anti-CD3 (tube 3) in a 100- l volume for 15 min in the dark
at room temperature (25 C). The samples were washed twice with PBS-
FCS, followed by the addition of 500  l PBS with 1% paraformaldehyde to
tubes 1 and 2 or 400  l 1  BD Annexin V binding buffer to tube 3. The
Annexin V–PI was analyzed by flow cytometry within 1 h, and other sam-
ples were stored at 4 C in the dark and analyzed within 24 h. A total of
50,000 events were counted within the lymphocyte gate for each samples.
IL-2 assay. PBMC culture media were collected, and IL-2 concentrations
were determined by a human IL-2 ELISA kit (R&D Systems), according to
the manufacturer’s protocol. ODs were measured at 450 nm with a multilabel
counter (Wallac Victor2 1420; PerkinElmer Life and Analytical Sciences).
Statistical analysis. Results of cell surface molecule and expression, apop-
tosis index, and secreted IL-2 were expressed as means   SD or as median.
Statistical analysis of these results was done by the one-way analysis of vari-
ance test. Because the expression levels of FAS and FASL on T cells might
be influenced by the activation status of T cells (37), an analysis of covari-
ance was performed when analyzing FAS/FASL expression by using the ex-
pression level of CD25 /CD4  cells and the concentration of IL-2 in cell
culture media as covariates. A p-value of  0.05 was used as the criterion of
statistical significance, and all statistical tests were two-sided tests. The asso-
ciation between FAS and FASL polymorphisms and the risk of cervical car-
cinoma was estimated using ORs and their 95% CIs, which were calculated
by unconditional logistic regression. All the ORs were adjusted for age and
smoking status. We tested the null hypotheses of additive and multiplicative
gene–gene interactions between the FAS and FASL polymorphisms and
evaluated departures from additive and multiplicative interaction models
(38) by including main effect variables and their product terms in the logis-
tic regression model. All analyses were performed with Statistical Analysis
System software (version 6.12; SAS Institute). Haplotype frequencies and
linkage disequilibrium coefficient were estimated using PHASE (39) and
2LD software (40).
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